Gunma University Graduate School of Medicine, Maebashi, Japan.
Arthritis Rheumatol. 2019 Feb;71(2):302-314. doi: 10.1002/art.40701. Epub 2019 Jan 4.
Several studies have demonstrated that the secreted glycoprotein and integrin ligand milk fat globule-associated protein with epidermal growth factor- and factor VIII-like domains (MFG-E8) negatively regulates fibrosis in the liver, lungs, and respiratory tract. However, the mechanisms and roles of MFG-E8 in skin fibrosis in systemic sclerosis (SSc) have not been characterized. We undertook this study to elucidate the role of MFG-E8 in skin fibrosis in SSc.
We assessed expression of MFG-E8 in the skin and serum in SSc patients. We examined the effect of recombinant MFG-E8 (rMFG-E8) on latent transforming growth factor β (TGFβ)-induced gene/protein expression in SSc fibroblasts. We examined the effects of deficiency or administration of MFG-E8 on fibrosis mouse models.
We demonstrated that MFG-E8 expression around dermal blood vessels and the serum MFG-E8 level in SSc patients (n = 7 and n = 44, respectively) were lower than those in healthy individuals (n = 6 and n = 28, respectively). Treatment with rMFG-E8 significantly inhibited latent TGFβ-induced expression of type I collagen, α-smooth muscle actin, and CCN2 in SSc fibroblasts (n = 3-8), which suggested that MFG-E8 inhibited activation of latent TGFβ as well as TGFβ signaling via binding to αv integrin. In a mouse model of bleomycin-induced fibrosis (n = 5-8) and in a TSK mouse model (a genetic model of SSc) (n = 5-10), deficient expression of MFG-E8 significantly enhanced both pulmonary and skin fibrosis, and administration of rMFG-E8 significantly inhibited bleomycin-induced dermal fibrosis.
These results suggest that vasculopathy-induced dysfunction of pericytes and endothelial cells, the main cells secreting MFG-E8, may be associated with the decreased expression of MFG-E8 in SSc and that the deficient inhibitory regulation of latent TGFβ-induced skin fibrosis by MFG-E8 may be involved in the pathogenesis of SSc and may be a therapeutic target for fibrosis in SSc patients.
多项研究表明,分泌糖蛋白和整合素配体乳脂肪球相关蛋白与表皮生长因子和因子 VIII 样结构域(MFG-E8)可负向调节肝脏、肺部和呼吸道的纤维化。然而,MFG-E8 在系统性硬化症(SSc)皮肤纤维化中的机制和作用尚未阐明。我们进行了这项研究,以阐明 MFG-E8 在 SSc 皮肤纤维化中的作用。
我们评估了 MFG-E8 在 SSc 患者皮肤和血清中的表达。我们研究了重组 MFG-E8(rMFG-E8)对 SSc 成纤维细胞中潜伏转化生长因子β(TGFβ)诱导的基因/蛋白表达的影响。我们研究了 MFG-E8 缺乏或给药对纤维化小鼠模型的影响。
我们证明了 MFG-E8 在 SSc 患者(n=7 和 n=44)真皮血管周围的表达和血清 MFG-E8 水平低于健康个体(n=6 和 n=28)。rMFG-E8 治疗显著抑制 SSc 成纤维细胞中潜伏 TGFβ诱导的 I 型胶原、α-平滑肌肌动蛋白和 CCN2 的表达(n=3-8),这表明 MFG-E8 通过与 αv 整合素结合抑制潜伏 TGFβ的激活和 TGFβ 信号转导。在博来霉素诱导的纤维化小鼠模型(n=5-8)和 TSK 小鼠模型(SSc 的遗传模型)(n=5-10)中,MFG-E8 表达缺陷显著增强肺和皮肤纤维化,rMFG-E8 给药显著抑制博来霉素诱导的皮肤纤维化。
这些结果表明,血管病变诱导的周细胞和内皮细胞功能障碍,这是 MFG-E8 的主要分泌细胞,可能与 SSc 中 MFG-E8 表达降低有关,MFG-E8 对潜伏 TGFβ诱导的皮肤纤维化的抑制调节缺陷可能与 SSc 的发病机制有关,可能成为 SSc 患者纤维化的治疗靶点。